Article
Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes.
Neuro-oncology - 3 Oct 2022
Zhang Yalan, Lucas Calixto-Hope G, Young Jacob S, Morshed Ramin A, McCoy Lucie, Oberheim Bush Nancy Ann, Taylor Jennie W, Daras Mariza, Butowski Nicholas A, Villanueva-Meyer Javier E, Cha Soonmee, Wrensch Margaret, Wiencke John K, Lee Julieann C, Pekmezci Melike, Phillips Joanna J, Perry Arie, Bollen Andrew W, Aghi Manish K, Theodosopoulos Philip, Chang Edward F, Hervey-Jumper Shawn L, Berger Mitchel S, Clarke Jennifer L, Chang Susan M, Molinaro Annette M, Solomon David A
Abstract excerpt
BACKGROUND: Genomic profiling studies of diffuse gliomas have led to new improved classification schemes that better predict patient outcomes compared to conventional histomorphology alone. One example is the recognition that patients with IDH-wildtype diffuse astrocytic gliomas demonstrating lower-grade histologic features but genomic and/or epigenomic profile characteristic of glioblastoma typically have poor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.